Journal of Neuro-Oncology

, Volume 92, Issue 2, pp 149–155

An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma

  • Andrew D. Norden
  • Jan Drappatz
  • Alona Muzikansky
  • Karly David
  • Mary Gerard
  • M. Brenna McNamara
  • Phuong Phan
  • Ainsley Ross
  • Santosh Kesari
  • Patrick Y. Wen
Clinical Study - Patient Study

Abstract

Recent clinical trial results suggest that anti-angiogenic therapy may be effective against recurrent malignant glioma. Though these treatments prolong progression-free survival, the extent to which they prolong overall survival is unknown. We pooled data from 34 patients treated at a single institution on phase II clinical trials of bevacizumab and cediranib, and we compared these data to 18 patients treated on clinical trials of cytotoxic chemotherapies. In univariate and multivariate analyses, treatment group was a significant predictor of progression-free but not overall survival. Median progression-free survival was 8 vs. 22 weeks in patients treated with cytotoxic as compared to anti-angiogenic therapy (P = 0.01). Median overall survival was nearly identical in the two groups (39 vs. 37 weeks). The results of this exploratory analysis suggest that anti-angiogenic therapy may fail to prolong overall survival in patients with recurrent malignant glioma. If this conclusion proves correct, progression-free survival may be an inappropriate endpoint for phase II trials of anti-angiogenic therapies.

Keywords

Malignant glioma Anti-angiogenic therapy Progression-free survival 

References

  1. 1.
    Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572–2578PubMedGoogle Scholar
  2. 2.
    Yung W, Albright R, Olson J, Fredericks R, Fink K, Prados M, Brada M, Spence A, Hohl R, Shapiro W, Glantz M, Greenberg H, Selker R, Vick N, Rampling R, Friedman H, Phillips P, Bruner J, Yue N, Osoba D, Zaknoen S, Levin V (2000) A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–593. doi:10.1054/bjoc.2000.1316 PubMedCrossRefGoogle Scholar
  3. 3.
    Yung WK, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O’Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA (1999) Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. J Clin Oncol 17:2762–2771PubMedGoogle Scholar
  4. 4.
    Vredenburgh JJ, Desjardins A, Herndon JEII, Dowell JM, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Wagner M, Bigner DD, Friedman AH, Friedman HS (2007) Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13:1253–1259. doi:10.1158/1078-0432.CCR-06-2309 PubMedCrossRefGoogle Scholar
  5. 5.
    Cloughesy T, Prados M, Wen P, Mikkelson T, Abrey L, Schiff D, Yung WK, Paleologos N, Nicholas MK, Dorr A, Zheng M, Dimery I, Friedman H (2007) A phase II, randomized, non-comparative clinical trial of bevacizumab alone or in combination with CPT-11 prolongs 6-month PFS in recurrent, treatment-refractory glioblastoma. Society for Neuro-Oncology 12th Annual MeetingGoogle Scholar
  6. 6.
    Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95. doi:10.1016/j.ccr.2006.11.021 PubMedCrossRefGoogle Scholar
  7. 7.
    Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD (2008) Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol 10:162–170. doi:10.1215/15228517-2007-062 PubMedCrossRefGoogle Scholar
  8. 8.
    Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  9. 9.
    Lassman AB, Iwamoto FM, Gutin PH, Abrey LE (2008) Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM). J Clin Oncol 26:2028Google Scholar
  10. 10.
    Narayana A, Raza S, Golfinos JG, Johnson G, Knopp EA, Zagzag D, Fischer I, Medabalmi P, Eagan P, Gruber ML (2008) Bevacizumab therapy in recurrent high grade glioma: impact on local control and survival. J Clin Oncol 26:13000Google Scholar
  11. 11.
    Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787. doi:10.1212/01.wnl.0000304121.57857.38 PubMedCrossRefGoogle Scholar
  12. 12.
    Zuniga RM, Torcuator R, Doyle T, Anderson J, Jain R, Orley J, Rosenblum M, Mikkelsen T (2008) Retrospective analysis of patterns of recurrence seen on MRI in patients with recurrent glioblastoma multiforme treated with bevacizumab plus irinotecan. J Clin Oncol 26:13013Google Scholar
  13. 13.
    Cloughesy TF, Prados MD, Mikkelsen T, Abrey LE, Schiff D, Yung WK, Maoxia Z, Dimery I, Friedman HS (2008) A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM). J Clin Oncol 26:2010bGoogle Scholar
  14. 14.
    Vredenburgh JJ, Desjardins A, Herndon JEII, Marcello J, Reardon DA, Quinn JA, Rich JN, Sathornsumetee S, Gururangan S, Sampson J, Wagner M, Bailey L, Bigner DD, Friedman AH, Friedman HS (2007) Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722–4729. doi:10.1200/JCO.2007.12.2440 PubMedCrossRefGoogle Scholar
  15. 15.
    Guiu S, Taillibert S, Chinot O, Taillandier L, Honnorat J, Dietrich PY, Maire JP, Guillamo JS, Guiu B, Catry-Thomas I, Capelle F, Thiebaut A, Cartalat-Carel S, Deville C, Fumoleau P, Desjardins A, Xuan KH, Chauffert B (2008) Bevacizumab/Irinotecan. An active treatment for recurrent high grade gliomas: Preliminary results of an ANOCEF Multicenter Study. Rev Neurol (Paris) 164:588–594 doi:10.1016/j.neurol.2008.04.003 Google Scholar
  16. 16.
    Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF (2006) MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66:1258–1260. doi:10.1212/01.wnl.0000208958.29600.87 PubMedCrossRefGoogle Scholar
  17. 17.
    Stark Vance V (2005) Bevacizumab (Avastin®) and CPT-11 (Camptosar®) in the Treatment of Relapsed Malignant Glioma. Neuro Oncol 7:369Google Scholar
  18. 18.
    Quant E, Norden AD, Drappatz J, Ciampa A, Doherty L, LaFrankie D, Kesari S, Wen PY (2008) Role of a second chemotherapy in recurrent malignant glioma patients who progress on a bevacizumab-containing regimen. J Clin Oncol 26:2008Google Scholar
  19. 19.
    Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, Kozin SV, Petit L, Jain RK, Chung DC, Sahani DV, Kalva SP, Cohen KS, Scadden DT, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Shellito PC, Mino-Kenudson M, Lauwers GY (2005) Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 23:8136–8139. doi:10.1200/JCO.2005.02.5635 PubMedCrossRefGoogle Scholar
  20. 20.
    Sorensen AG, Batchelor TT, Wen PY, Zhang WT, Jain RK Response criteria for glioma (2008) Nat Clin Pract Oncol 5:634–644Google Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • Andrew D. Norden
    • 1
    • 2
    • 3
  • Jan Drappatz
    • 1
    • 2
    • 3
  • Alona Muzikansky
    • 4
  • Karly David
    • 2
  • Mary Gerard
    • 2
  • M. Brenna McNamara
    • 2
  • Phuong Phan
    • 2
  • Ainsley Ross
    • 2
  • Santosh Kesari
    • 1
    • 2
    • 3
  • Patrick Y. Wen
    • 1
    • 2
    • 3
  1. 1.Division of Neuro-Oncology, Department of NeurologyBrigham and Women’s HospitalBostonUSA
  2. 2.Center for Neuro-Oncology, Dana-Farber Cancer InstituteBostonUSA
  3. 3.Harvard Medical SchoolBostonUSA
  4. 4.Massachusetts General Hospital Biostatistics CenterBostonUSA

Personalised recommendations